Anebulo Pharmaceuticals (ANEB) Interest Expenses (2020 - 2025)
Anebulo Pharmaceuticals (ANEB) posted quarterly Interest Expenses of $17439.0 for Q4 2025, down 82.56% year-over-year from $100000.0 in Q4 2024, and down 98.82% quarter-over-quarter from $1.5 million in Q3 2025.
Anebulo Pharmaceuticals (ANEB) Interest Expenses (2020 - 2025) Analysis & Trends
Anebulo Pharmaceuticals (ANEB) has reported Interest Expenses for 6 consecutive years, with $17439.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Interest Expenses fell 82.56% year-over-year to $17439.0; the TTM figure through Dec 2025 stood at $398046.0 (up 88.46% YoY), while the FY2025 annual figure was $400000.0, up 100.0% from the prior year.
- Interest Expenses eased to $17439.0 in Q4 2025 per ANEB's latest filing, from $1.5 million in the prior quarter.
- Across five years, Interest Expenses topped out at $4.7 million in Q2 2023 and bottomed at -$1286.0 in Q2 2021.
- Historically, Interest Expenses has averaged $1.1 million across 5 years, with a median of $355423.0 in 2022.
- Annual changes were most pronounced in 2021 — Interest Expenses slumped 103.68% — and 2022, when it jumped 173466.41%.
- Anebulo Pharmaceuticals' Interest Expenses stood at $2.4 million in 2021, then plunged by 94.27% to $137362.0 in 2022, then changed by 0.0% to $137362.0 in 2023, then slipped by 27.2% to $100000.0 in 2024, then plunged by 82.56% to $17439.0 in 2025.
- Business Quant data shows ANEB's Interest Expenses at $17439.0 in Q4 2025, $1.5 million in Q3 2025, and $35425.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 11.00 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 39.74 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 82.05 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 20.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 93.62 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -4.89 Mn |
| 10 | Anebulo Pharmaceuticals | 16.43 Mn | 16.43 Mn | - | 17,439.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 17,439.00 |
| Dec 31, 2025 | 17,439.00 |
| Sep 30, 2025 | 1.48 Mn |
| Sep 30, 2025 | 1.48 Mn |
| Jun 30, 2025 | 35,425.00 |
| Jun 30, 2025 | 35,425.00 |
| Mar 31, 2025 | 245,182.00 |
| Mar 31, 2025 | 245,182.00 |
| Dec 31, 2024 | 100,000.00 |
| Dec 31, 2024 | 100,000.00 |
| Sep 30, 2024 | 100,000.00 |
| Sep 30, 2024 | 100,000.00 |
| Jun 30, 2024 | 108,466.00 |
| Jun 30, 2024 | 108,466.00 |
| Mar 31, 2024 | 352,930.00 |
| Mar 31, 2024 | 352,930.00 |
| Dec 31, 2023 | 137,362.00 |
| Dec 31, 2023 | 137,362.00 |
| Sep 30, 2023 | 565,862.00 |
| Sep 30, 2023 | 565,862.00 |